Armistice Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

Armistice Capital’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$58.7M	Sell	13,932,000 -1,096,000	-7%	-$4.22M	0.72%	20
2026 Q1	$52.7M	Sell	15,028,000 -997,000	-6%	-$4.09M	0.94%	16
2025 Q4	$54M	Sell	16,025,000 -125,000	-0.8%	-$325K	0.64%	23
2025 Q3	$21.2M	Hold	16,150,000	–	–	0.31%	49
2025 Q2	$11.6M	Buy	16,150,000 +2,450,000	+18%	+$1.92M	0.2%	64
2025 Q1	$20.1M	Buy	13,700,000 +4,232,000	+45%	+$10.1M	0.3%	62
2024 Q4	$41.9M	Buy	9,468,000 +1,268,000	+15%	+$5.14M	0.57%	33
2024 Q3	$33.8M	Buy	8,200,000 +400,000	+5%	+$2.15M	0.54%	34
2024 Q2	$50.9M	Buy	7,800,000 +2,400,000	+44%	+$17M	0.64%	23
2024 Q1	$47M	Sell	5,400,000 -300,000	-5%	-$3.64M	0.62%	23
2023 Q4	$65.2M	Buy	5,700,000 +2,244,000	+65%	+$22.2M	0.89%	19
2023 Q3	$33.3M	Buy	+3,456,000	New	+$33.9M	0.51%	38

Other funds holding IRWD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Armistice Capital's IRWD Position: Q2 2026 in Review

Armistice Capital reduced its Ironwood Pharmaceuticals (IRWD) stake by 7.3% in Q2 2026, selling an estimated $4.22M and leaving 13,932,000 shares worth $58.7M. The position accounts for 0.72% of the portfolio, ranked #20.

Armistice Capital first reported a position in IRWD in Q3 2023 and has held it in 12 quarters since. The position peaked at $65.2M in Q4 2023. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

Armistice Capital held 13,932,000 shares of Ironwood Pharmaceuticals worth $58.7M as of Q2 2026.
Armistice Capital sold 1,096,000 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $4.22M.
Ironwood Pharmaceuticals made up 0.72% of Armistice Capital's portfolio in Q2 2026, its #20 holding.
Armistice Capital first reported a position in Ironwood Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Armistice Capital's Ironwood Pharmaceuticals position peaked at $65.2M in Q4 2023.
212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.